Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

G L Uy, L J Costa, P N Hari, M J Zhang, J X Huang, K C Anderson, C N Bredeson, N S Callander, R F Cornell, M A D Perez, A Dispenzieri, C O Freytes, R P Gale, A Garfall, M A Gertz, J Gibson, M Hamadani, H M Lazarus, M E Kalaycio, R T KambleM A Kharfan-Dabaja, A Y Krishnan, S K Kumar, R A Kyle, H J Landau, C H Lee, A Maiolino, D I Marks, T M Mark, R Munker, T Nishihori, R F Olsson, M Ramanathan, T E Rodriguez, A A Saad, B N Savani, G J Schiller, H C Schouten, J R Schriber, E Scott, S Seo, M Sharma, S Ganguly, E A Stadtmauer, J Tay, L B To, D H Vesole, D T Vogl, J L Wagner, B Wirk, W A Wood, A D'Souza*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.
Original languageEnglish
Pages (from-to)1513
Number of pages1
JournalBone Marrow Transplantation
Issue number12
Publication statusPublished - 2015

Cite this